Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Our TAC platform offers competitive advantages over CAR-T and TCR therapies, including:
- Co-opting the natural T cell signaling pathways
- Design of a safer and more effective T cell therapy
- Demonstration of superiority in preclinical models
- A strong intellectual property platform including composition of matter applications, and freedom to operate
- An expanding pipeline including solid and liquid tumor indications
Triumvira’s lead therapeutic candidate, CD19-TAC01, is a CD19-directed T cell product for the treatment of B cell malignancies and is anticipated to enter Phase I clinical trials in early 2019 in patients with diffuse large B cell lymphoma (DLBCL). The company is also developing a series of products for solid tumors.
Triumvira is led by Dr. Paul Lammers, CEO & President, and an experienced management team with operational, clinic and product development expertise. Spanning the United States and Canada, our headquarters are in Austin, Texas and our research facilities are in Hamilton, Ontario.